INTRODUCTION
Rheumatoid arthritis (RA) is one of the most common causes of chronic arthritis and results in severe joint damage and a shorter life span. 1 Genetic factors have been shown to contribute to the onset of RA. 2 Among the genetic susceptibility loci detected to date, HLA-DRB1 has a strong impact on the predisposition to RA and has been repeatedly shown to be associated with RA in an ethnicity-independent manner. 3 It is widely accepted that the shared epitope (SE), a common amino acid sequence located from the 70th to the 74th amino acids of the HLA-DR β chain, explains the associations of specifi c HLA-DRB1 alleles with RA. 4 Anticitrullinated protein antibodies (ACPA) are a highly specifi c marker of RA. 5 6 Recent data have shown that the SE is associated with ACPApositive RA but not associated or only weakly associated with ACPA-negative RA. 7 -9 Many of the non-HLA susceptibility genes for RA detected to date, such as PTPN22 10 and CTLA4 11 have been shown to be associated with ACPA-positive RA alone, and no association between these genes and ACPA-negative RA has been detected. These fi ndings suggest that ACPA-negative RA is genetically distinct from ACPA-positive RA.
Among HLA-DRB1 molecules, HLA-DR3 12 and HLA-DR13 13 were reported to be associated with ACPA-negative RA in populations of European descent, but the same results were not obtained in a meta-analysis of a large Caucasian cohort. 14 In Asian populations, there has only been a small study which showed that HLA-DRB1*09:01 might be associated with ACPA-negative RA, 15 while SEs, especially DRB1*04:05, *04:01 and *01:01, were associated with RA and ACPA-positive RA. 15 16 Thus, no specifi c alleles that convey susceptibility to, or are protective against, ACPAnegative RA have been identifi ed in populations of European or Asian descent. In this large-scale Japanese case-control association study, we show that HLA-DRB1*12:01, *14:03 and *04:05 are susceptibility alleles for ACPA-negative RA and that HLA-DRB1*13:02 and *15:02 are protective against ACPA-negative RA. We also identifi ed multiple diplotypes that convey susceptibility to, or are protective against, ACPA-negative RA.
MATERIALS AND METHODS Study subjects
DNA samples were collected at Kyoto University Hospital from 184 patients with RA who were negative for ACPA, as reported previously, 7 and another 184 patients with RA without ACPA were recruited at Tokyo Women's Medical University. These two sample groups were used as the fi rst set. Independent DNA samples were collected from 501 ACPA-negative patients with RA at RIKEN under the support of BioBank Japan and were used as the second set. The 501 cases in the second set are a fraction of 2410 RA cases included in another manuscript (K Shimane et al , unpublished data). All patients were Japanese and diagnosed by rheumatologists to fulfi l the 1987 American College of Rheumatology revised criteria for RA. 17 A fi rst set of control DNA samples were collected from 1508 healthy control subjects at Aichi Cancer Center Hospital and from the DNA banks of the Pharma SNP Consortium, which contains DNA samples from healthy Japanese volunteers. 18 The second set of control DNA samples were collected from 500 healthy volunteers at the HLA laboratory. This study was approved by the local ethical committees at each institution, and written informed consent was obtained from all patients. Basic information about cases and controls is shown in table 1 .
ACPA detection
ACPA were detected with the MESACUP CCP ELISA kit (Medical and Biological Laboratories Co, Ltd, Nagoya, Japan) according to the manufacturer's instructions at each institution. A cut-off value of 4.5 U/ml was used to assess ACPA positivity.
HLA-DRB1 genotyping
HLA-DRB1 typing was carried out with the WAKFlow system and described in detail elsewhere. 7 In the 184 cases collected at Kyoto University and all the controls in the two sets, genotyping was performed at the HLA laboratory (Kyoto, Japan), whereas it was carried out at RIKEN for all 501 cases in the second set. HLA-DRB1 genotyping of the 184 cases collected at Tokyo Women's Medical University was performed by a sequencingbased typing method using the AlleleSEQR HLA-DRB1 typing kit (Abbott, Tokyo, Japan ), and allele assignment was performed using the Assign software.
The following HLA-DRB1 alleles were classifi ed as belonging to the SE: DRB1*01:01, *01:02, *04:01, *04:04, *04:05, *04:08, *04:10, *04:13, *04:16, *10:01, *13:03, *14:02 and *14:06.
Statistical analysis
The frequency of each genotype or diplotype among the ACPAnegative patients with RA was compared with that in the controls using a χ 2 test or Fisher's exact test. Ninety-fi ve percent CIs, p values and ORs were also calculated. The relative risk (RR) of ACPA-negative susceptibility induced by homozygosity for each allele was calculated to estimate the dosage effect. We performed 1000 permutation tests to confi rm the associations found for each allele. Logistic regression analysis was used to evaluate the effects of alleles by adjusting for the infl uence of other alleles. Statistical analysis was performed using the R statistic system ( http://www.R-project.org ) or SPSS (version 18). The power calculation was performed using an online power calculator ( http://pngu.mgh.harvard.edu/~purcell/gpc/ ).
RESULTS

Genotyping of the fi rst set
We performed HLA-DRB1 genotyping in the 368 ACPAnegative patients with RA and 1508 healthy controls in the fi rst set to compare the allele frequency of each genotype between the cases and controls ( table 1 ). Tables 2 and 3 show the main results of our association study for single alleles and diplotypes, respectively. More detailed results are given in the online supplementary tables 1 and 2.
The SE showed a weak association with moderate effect (p = 0.039), mainly due to HLA-DRB1*04:05. Among the other HLA-DRB1 alleles, HLA-DRB1*14:03, *12:01, and *09:01 resulted in moderate to potential susceptibility to ACPA-negative RA (p = 0.022, 0.10, and 0.10, respectively). DRB1*13:02, *04:03, and *15:02 showed moderate to potentially protective effects (p = 0.0072, 0.059, and 0.12, respectively).
Replication in the second set and combined analysis
We performed HLA-DRB1 genotyping of samples in the second set to replicate the results found in the fi rst set, using the DNA samples from 501 ACPA-negative patients with RA and 500 sexmatched healthy controls and combined the results of the two association studies.
Among the susceptibility alleles found in the fi rst set, HLA-DRB1*12:01 was confi rmed to display a susceptible association (p=0.010 and 0.000088 for the second set and combined study, respectively; table 2 ). The susceptibility tendencies of *04:05 and *14:03 were replicated in the second set, and these alleles showed moderate associations with susceptibility to ACPAnegative RA in the combined analysis (p = 0.0063 and 0.0043, respectively). DRB1*09:01 and *14:05 showed potential susceptibility to ACPA-negative RA in the pooled study (p = 0.062 and 0.080, respectively). The SE showed a weak association with susceptibility to ACPA-negative RA in the combined study (p = 0.016), but we could not detect any dosage effect ( table 3 and fi gure 1 ). Among the protective alleles detected in the fi rst set, the protective effect of DRB1*15:02 was successfully replicated (p = 0.002 and 0.00010 in the second set and combined study, respectively; table 2 ). Although the protective effect of DRB1*13:02 was not replicated in the second set, the combined analysis showed a signifi cant protective effect (p = 0.00059). The protective effect of DRB1*04:03 was confi rmed in the second set, and the combined study demonstrated a weak protective association (p = 0.038). To exclude the possibility that the associations of the susceptibility alleles were induced by the absence of protective alleles or vice versa, we applied logistic regression analysis. The logistic regression analysis suggested that none of the allelic associations-namely, those of HLA-DRB1*12:01, *14:03, *04:05, *13:02, and *15:02, depended on the effects of other alleles (online supplementary table 3 ). In addition, the permutation tests confi rmed the associations of these fi ve alleles (permutation p<0.0070, data not shown).
Next, we analysed the dosage effects of each protective or susceptibility allele. DRB1*12:01 showed a potential dosage effect, but only two patients were homozygous for DRB1*12:01 ( fi gure 1 ). We could not detect any dosage effects of HLA-DRB1*04:05 or the SE. No patients were homozygous for *14:03 group.bmj.com on February 9, 2012 -Published by ard.bmj.com Downloaded from in the cases or controls. Both DRB1*13:02 and *15:02 showed potential dosage effects.
Diplotype analysis
When we analysed the effects of HLA-DRB1 allele diplotypes on the predisposition to ACPA-negative RA, we found that a combination of DRB1*09:01 and *12:01 demonstrated susceptible effects in both sets (p = 0.025, 0.020 and 0.00013 in the fi rst, second and combined study, respectively; table 3 ). DRB1*08:03 homozygosity showed a weak susceptible association without any dosage effects ( table 3 , s upplementary table 1 ). Although we found no susceptibility effect of DRB1*08:02 homozygosity, the combination of DRB1*08:02 and *08:03 also resulted in weak susceptibility (supplementary table 2). When we analysed DR8 allele homozygosity, we found that it displayed a moderate susceptibility association in the combined analysis (p = 0.0070, table 3 ). Any combination of two of the three susceptibility alleles-namely, HLA-DRB1*12:01, *14:03, and *04:05, showed a potentially susceptible effect (supplementary table 2 ).
The HLA-DRB1*08:03 and *15:02 diplotype showed the strongest protective effect (p = 0.00011, table 3 ). We found that the diplotypes with protective effects (*08:03/*15:02, *15:02/*15:02 and *13:02/*15:02) all included HLA-DRB1*15:02 ( table 3 ) .
DISCUSSION
Recent studies have suggested that ACPA-negative RA is a genetically different subset of RA. 7 8 While SE is very strongly associated with ACPA-positive RA, it is reported as not associated or only weakly associated with ACPA-negative RA. In populations of European descent, HLA-DR3 and DR13 were reported to be susceptibility alleles, 12 13 but a recent meta-analysis of a large Caucasian cohort did not fi nd any such association. 14 In Japanese subjects, only DRB1*09:01 was reported to be associated with ACPA-negative RA, using small numbers of patients and controls (28 and 265, respectively). 15 16 HLA-DR3 is rare in the Japanese population, and we found only one HLA-DR3 allele in our cohorts.
Although genetic factors contribute to the development of ACPA-negative RA as much as ACPA-positive RA, 19 little is known about the ACPA-negative RA susceptibility alleles of HLA and non-HLA genes.
Here, we performed a case-control association study using a large number of ACPA-negative patients with RA and controls and showed that multiple alleles and diplotypes are associated with ACPA-negative RA in Japanese people. Although the controls in the fi rst set had different age and sex ratio values from those of the patients and we could not obtain age data for the 500 controls in the second set, the effects of the above-mentioned difference and lack of data on our results were considered to be limited. The HLA locus is located on chromosome 6 and is not affected by sex or age. Indeed, regression analysis did not signifi cantly alter our association results (data not shown).
Our study showed that HLA-DRB1*12:01 is strongly associated with ACPA-negative RA and that HLA-DRB1*14:03 and HLA-DRB1*04:05 in SE are moderately associated with ACPAnegative RA in Japanese people. All three susceptibility alleles showed susceptibility associations with ACPA-negative RA when found in combination with one of the other two alleles. Our data also suggested a dosage effect of HLA-DRB1*12:01, while no dosage effect of HLA-DRB1*04:05 was detected, with decreased OR of DRB1*04:05 in homozygotes compared with heterozygous patients. In addition, we showed that the HLA-DRB1*09:01 and HLADRB1*12:01 diplotype and HLA-DR8 homozygosity are strong susceptibility combinations for ACPAnegative RA. We also determined HLA-DRB1*13:02 and *15:02 as protective alleles against ACPA-negative RA with a potential dosage effect. The combination of DRB1*08:03 and *15:02 had a strong protective effect in our study. Using logistic regression analysis, we confi rmed that the effects of these susceptibility and protective alleles do not depend on each other (supplementary table 3). Although we searched for common amino acid sequences among the susceptibility alleles, we could not detect any meaningful sequences common to HLA-DRB1*12:01, *14:03, and/or *04:05. We also failed to detect a common amino acid sequence among the protective alleles HLA-DRB1*15:02 and *13:02.
Although the association of SE with ACPA-negative RA cannot be concluded, our large-scale study showed that it is weakly associated with ACPA-negative RA. As we observed a lower OR of the SE in homozygotes than in heterozygous patients, confi rmation of this association in other studies are needed. We consider that the SE is associated with ACPA-negative RA but has a much weaker effect than in ACPA-positive RA. Both the relatively small effect of SE on ACPA-negative RA and the small number of cases in previous reports might have resulted in nonsignifi cant p values for such tendencies. HLA-DRB1*12:01, which was found to be associated with ACPA-negative RA susceptibility in our study, was reported to be associated with type 1 diabetes mellitus (T1D) in Latin America, but no similar association has been reported in Japan. 20 21 While a Japanese study showed RA with the anti-glucose-6-phosphate isomerase antibody is associated with HLA-DRB1*12:01, 22 no large-scale studies have reported an association between HLA-DRB1*12:01 and RA. As RA shares susceptibility genes with T1D such as PTPN22 , 23 the determination of HLA-DRB1*12:01 as a potential common risk allele for both T1D and ACPAnegative RA is interesting. Although HLA-DRB1*12:01 showed a possible dosage effect, further confi rmation is necessary as only two homozygous patients were among the cases. The allele frequency of HLA-DRB1*12:01 in a European population is 1-4%, 24 and so far there are no reports showing an association with ACPA-negative RA. 14 HLA-DRB1*12:02, the other allele of HLA-DR12, showed no association with ACPA-negative RA.
HLA-DRB1*14:03 was reported to be associated with Grave's disease in Japanese patients, 25 but its role in RA is unknown. Although our samples did not contain any patients who were homozygous for the allele owing to its low allele frequency, it showed a moderate association with ACPA-negative RA susceptibility. Among the other non-SE DR14 alleles, DRB1*14:05 displayed a tendency towards ACPA-negative RA susceptibility, while *14:01 and *14:07 did not. In total, DR14 alleles, including *14:06 in SE, showed moderate susceptibility effects on ACPAnegative RA (supplementary table 1).
Although one European study suggested that HLA-DR15 has a protective effect against ACPA-negative RA, its effect on ACPAnegative RA has not been fully examined. 13 We showed that HLA-DR15 has strong protective effect against ACPA-negative RA and a possible dosage effect. HLA-DRB1*15:02 is reported to be associated with Japanese T1D in a protective manner. 21 Among HLA-DR13 alleles, HLADRB1*13:02 was reported to be protective against ACPA-positive RA. 26 27 Its protective effect was also reported in Japanese patients with RA. 16 Its effect on ACPA-negative RA has not been established. 13 14 Our study suggested that HLA-DRB1*13:02 has a protective effect against ACPA-negative RA. As the second set in our study did not show any differences in allele frequency between the patients and controls, further validation of our fi ndings is necessary. HLA-DRB1*13:01, a major component of DR13 in populations of European descent, had no effect in our study, where we included DRB1*13:01 in eight alleles in cases and 23 alleles in controls (p=0.59).
HLA-DR8 has also been reported to be associated with some arthropathic autoimmune diseases, such as juvenile idiopathic arthritis 28 and psoriatic arthritis 29 in European subjects. The associations indicate that these arthropathies share common pathological mechanisms. Interestingly, the combination of DR8 and DR15 had a strong protective effect against ACPAnegative RA. Considering that DR8 did not show susceptibility association as a single allele, it seems to induce ACPA-negative RA susceptibility in a recessive manner. Among the DR8 alleles, DRB1*08:03 appeared to have a strong effect on ACPA-negative RA susceptibility.
Although we did not detect a dosage effect of HLA-DRB1*04:03, it showed a potentially protective effect against ACPA-negative RA in the combined study. Further studies are necessary to confi rm the association.
As DRB1*09:01 has been shown to be associated with a decreased ACPA titre in ACPA-positive RA, 30 it is likely to be associated with ACPA-negative RA. While DRB1*09:01 showed a potential susceptibility association (p=0.062), the combination of DRB1*09:01 and *12:01 showed strong susceptibility association (p=0.00013). DRB1*09:01 also showed a possible dosage effect. From this viewpoint, we consider that DRB1*09:01 has a potential susceptibility effect on ACPA-negative RA. Owing to the relatively high allele frequency of DRB1*09:01, another independent association study or appropriate classifi cation of ACPA-negative RA could produce signifi cant results.
In addition to the different associations of the SE with ACPAnegative RA and ACPA-positive RA, we found multiple alleles associated with ACPA-negative RA that are not shared by ACPA-positive RA. These showed that ACPA-negative RA is a distinct subset of RA. Moreover, when we focused on ACPAnegative erosive RA to exclude the possibility of our results being affected by non-RA arthritic diseases, the effects of all the following alleles were maintained: *12:01, *14:03, *04:05, *13:02 and *15:02 (data not shown). This is the fi rst large-scale association study involving Japanese ACPA-negative patients with RA and the detection of multiple alleles and diplotypes associated with susceptibility to, or protection against, ACPA-negative RA. To evaluate whether our cohort had suffi cient power to detect HLA-DRB1 genotype associations, we applied a risk allele with 5% frequency in the general population (see 'Materials and methods'). Our power calculation showed that this study had power values of 81% for fi nding genotype associations with an OR of 1.4 at the 0.05 signifi cance level. When we set the OR to 1.2, our study had power values of 31%. These results suggest that our study has suffi cient power to detect associated alleles that are present in relatively high frequencies (such as 5%) and a moderate OR of 1.4. On the contrary, our study has insuffi cient power to detect associations involving a weak OR such as 1.2. There is a possibility that ACPA-negative RA is associated with more HLA-DRB1 alleles or diplotypes that display a low allele frequency and/or a low OR. Further studies using ACPA-negative RA samples in Japan are necessary to fi nd such associations.
While association studies using ACPA-negative patients with RA of European descent only found a few weak associations and none of them were subsequently replicated, our study successfully determined multiple alleles with relatively strong effects on ACPA-negative RA. From this viewpoint, we suppose that Japanese ACPA-negative patients with RA have a relatively similar genetic background compared to European patients. Population stratifi cation within European population may also be assumed. Nevertheless, the validation of our results in Asian countries is necessary, and large-scale genome-wide association studies of ACPA-negative RA are also required to elucidate the pathogenesis of ACPA-negative RA.
